JP2016505240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505240A5 JP2016505240A5 JP2015540826A JP2015540826A JP2016505240A5 JP 2016505240 A5 JP2016505240 A5 JP 2016505240A5 JP 2015540826 A JP2015540826 A JP 2015540826A JP 2015540826 A JP2015540826 A JP 2015540826A JP 2016505240 A5 JP2016505240 A5 JP 2016505240A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- complement
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims 54
- 230000001404 mediated effect Effects 0.000 claims 33
- 230000002829 reductive effect Effects 0.000 claims 33
- 102000016917 Complement C1 Human genes 0.000 claims 32
- 108010028774 Complement C1 Proteins 0.000 claims 32
- 230000000295 complement effect Effects 0.000 claims 32
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 29
- 238000000034 method Methods 0.000 claims 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 210000001519 tissue Anatomy 0.000 claims 19
- 239000012472 biological sample Substances 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 13
- 208000035475 disorder Diseases 0.000 claims 13
- 230000009467 reduction Effects 0.000 claims 12
- 230000024203 complement activation Effects 0.000 claims 10
- 210000000056 organ Anatomy 0.000 claims 10
- 239000000243 solution Substances 0.000 claims 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 239000000178 monomer Substances 0.000 claims 8
- 230000006872 improvement Effects 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 210000003743 erythrocyte Anatomy 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 5
- 239000008280 blood Substances 0.000 claims 5
- 230000009089 cytolysis Effects 0.000 claims 5
- 230000008021 deposition Effects 0.000 claims 5
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 230000008595 infiltration Effects 0.000 claims 4
- 238000001764 infiltration Methods 0.000 claims 4
- 210000000715 neuromuscular junction Anatomy 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 206010030113 Oedema Diseases 0.000 claims 3
- 206010057249 Phagocytosis Diseases 0.000 claims 3
- 208000003441 Transfusion reaction Diseases 0.000 claims 3
- 239000002738 chelating agent Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 210000003038 endothelium Anatomy 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000003384 imaging method Methods 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000000162 organ preservation solution Substances 0.000 claims 3
- 230000008782 phagocytosis Effects 0.000 claims 3
- 239000003761 preservation solution Substances 0.000 claims 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- 241000282693 Cercopithecidae Species 0.000 claims 2
- 229940123457 Free radical scavenger Drugs 0.000 claims 2
- 108010024636 Glutathione Proteins 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 229960005305 adenosine Drugs 0.000 claims 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 2
- 229960003459 allopurinol Drugs 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000008499 blood brain barrier function Effects 0.000 claims 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960003180 glutathione Drugs 0.000 claims 2
- 210000003630 histaminocyte Anatomy 0.000 claims 2
- 229940050526 hydroxyethylstarch Drugs 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 210000004498 neuroglial cell Anatomy 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- BIRNWOIQDVFTSP-WWNCWODVSA-M potassium (2R,3R,4R,5R)-2,3,5,6-tetrahydroxy-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoate Chemical compound [K+].OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C([O-])=O BIRNWOIQDVFTSP-WWNCWODVSA-M 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 239000002516 radical scavenger Substances 0.000 claims 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 229920001059 synthetic polymer Polymers 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 108010028778 Complement C4 Proteins 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 206010039509 Scab Diseases 0.000 claims 1
- 206010040840 Skin erosion Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000020411 cell activation Effects 0.000 claims 1
- 230000006727 cell loss Effects 0.000 claims 1
- 230000006037 cell lysis Effects 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000013872 defecation Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 210000003722 extracellular fluid Anatomy 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000007277 glial cell activation Effects 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 210000003709 heart valve Anatomy 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000003907 kidney function Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 210000000274 microglia Anatomy 0.000 claims 1
- 230000027939 micturition Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000031978 negative regulation of complement activation Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 231100000862 numbness Toxicity 0.000 claims 1
- 210000004248 oligodendroglia Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 210000001179 synovial fluid Anatomy 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 230000008728 vascular permeability Effects 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 230000004304 visual acuity Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721916P | 2012-11-02 | 2012-11-02 | |
| US61/721,916 | 2012-11-02 | ||
| US201361754123P | 2013-01-18 | 2013-01-18 | |
| US61/754,123 | 2013-01-18 | ||
| US201361779180P | 2013-03-13 | 2013-03-13 | |
| US61/779,180 | 2013-03-13 | ||
| US201361846402P | 2013-07-15 | 2013-07-15 | |
| US61/846,402 | 2013-07-15 | ||
| PCT/US2013/068095 WO2014071206A1 (en) | 2012-11-02 | 2013-11-01 | Anti-complement c1s antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019111910A Division JP6860618B2 (ja) | 2012-11-02 | 2019-06-17 | 抗補体Ｃ１ｓ抗体とそれらの用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505240A JP2016505240A (ja) | 2016-02-25 |
| JP2016505240A5 true JP2016505240A5 (enExample) | 2016-12-22 |
| JP6543572B2 JP6543572B2 (ja) | 2019-07-10 |
Family
ID=50622568
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540826A Active JP6543572B2 (ja) | 2012-11-02 | 2013-11-01 | 抗補体Ｃ１ｓ抗体とそれらの用途 |
| JP2019111910A Active JP6860618B2 (ja) | 2012-11-02 | 2019-06-17 | 抗補体Ｃ１ｓ抗体とそれらの用途 |
| JP2021052645A Active JP7210629B2 (ja) | 2012-11-02 | 2021-03-26 | 抗補体Ｃ１ｓ抗体とそれらの用途 |
| JP2023002363A Withdrawn JP2023052318A (ja) | 2012-11-02 | 2023-01-11 | 抗補体Ｃ１ｓ抗体とそれらの用途 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019111910A Active JP6860618B2 (ja) | 2012-11-02 | 2019-06-17 | 抗補体Ｃ１ｓ抗体とそれらの用途 |
| JP2021052645A Active JP7210629B2 (ja) | 2012-11-02 | 2021-03-26 | 抗補体Ｃ１ｓ抗体とそれらの用途 |
| JP2023002363A Withdrawn JP2023052318A (ja) | 2012-11-02 | 2023-01-11 | 抗補体Ｃ１ｓ抗体とそれらの用途 |
Country Status (21)
| Country | Link |
|---|---|
| US (10) | US8945562B2 (enExample) |
| EP (2) | EP2914291B1 (enExample) |
| JP (4) | JP6543572B2 (enExample) |
| CN (3) | CN104884088B (enExample) |
| AU (4) | AU2013337638B2 (enExample) |
| CA (1) | CA2889197A1 (enExample) |
| DK (1) | DK2914291T3 (enExample) |
| ES (1) | ES2912396T3 (enExample) |
| FI (1) | FIC20230015I1 (enExample) |
| FR (1) | FR23C1019I2 (enExample) |
| GB (1) | GB2509260B (enExample) |
| HR (1) | HRP20220637T1 (enExample) |
| HU (1) | HUS2300017I1 (enExample) |
| LT (2) | LT2914291T (enExample) |
| LU (1) | LUC00303I2 (enExample) |
| NL (1) | NL301232I2 (enExample) |
| NO (1) | NO2023018I1 (enExample) |
| PL (1) | PL2914291T3 (enExample) |
| PT (1) | PT2914291T (enExample) |
| RS (1) | RS63212B1 (enExample) |
| WO (1) | WO2014071206A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9555032B2 (en) * | 2007-06-13 | 2017-01-31 | Research Development Foundation | Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling |
| EP2346906A4 (en) | 2008-10-15 | 2013-04-24 | Angiochem Inc | CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE |
| EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
| CN104870475B (zh) | 2012-10-25 | 2019-11-08 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| CA2889197A1 (en) * | 2012-11-02 | 2014-05-08 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| US20160090425A1 (en) * | 2013-05-15 | 2016-03-31 | Annexon, Inc. | Anti-complement factor c1s antibodies and uses thereof |
| BR112016000106B1 (pt) | 2013-07-09 | 2023-11-21 | Annexon, Inc. | Anticorpos anti-c1q e usos dos mesmos, célula de hibridoma, composição farmacêutica e métodos de detecção de sinapses em uma amostra biológica referências cruzadas a pedidos relacionados |
| US10258699B2 (en) * | 2014-10-24 | 2019-04-16 | University Of Science And Technology Of China | Angiopep and derivatives thereof for imaging amyloids |
| WO2016073685A1 (en) | 2014-11-05 | 2016-05-12 | Annexon, Inc. | Humanized anti-complement factor c1q antibodies and uses thereof |
| PT3280440T (pt) * | 2015-04-06 | 2023-02-14 | Bioverativ Usa Inc | Anticorpos anti-c1s humanizados e métodos de utilização destes |
| CA2989400A1 (en) | 2015-06-15 | 2016-12-22 | Angiochem Inc. | Ang1005 for the treatment of leptomeningeal carcinomatosis |
| WO2016210172A1 (en) * | 2015-06-26 | 2016-12-29 | True North Therapeutics, Inc. | Methods of treating autoimmune and alloimmune disorders |
| EP3380518B1 (en) | 2015-11-24 | 2026-03-25 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
| US20190033329A1 (en) * | 2016-01-25 | 2019-01-31 | President And Fellows Of Harvard College | Methods and compositions for detecting and treating schizophrenia |
| US10934347B2 (en) * | 2016-04-04 | 2021-03-02 | Genzyme Corporation | Anti-complement factor BB antibodies and uses thereof |
| WO2017196960A1 (en) * | 2016-05-10 | 2017-11-16 | Annexon, Inc. | Anti-complement factor c4/c4b antibodies and uses thereof |
| CN116554320A (zh) * | 2016-10-12 | 2023-08-08 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| BR112019018950A2 (pt) * | 2017-03-14 | 2020-04-22 | Bioverativ Usa Inc. | métodos para tratamento de doenças e distúrbios mediados por complemento |
| EP3710589A4 (en) * | 2017-11-14 | 2021-11-10 | Chugai Seiyaku Kabushiki Kaisha | ANTI-C1S ANTIBODIES AND METHOD OF USING |
| US20210318335A1 (en) * | 2018-08-28 | 2021-10-14 | Duke University | Biomarkers, compositions, and methods for diagnosing and treating subjects exposed to protein/heparin complexes |
| BR112021011107A2 (pt) * | 2018-12-13 | 2021-12-14 | Argenx Bvba | Anticorpos para o fator de complemento humano c2b e métodos de uso |
| BR112021021689A2 (pt) | 2019-05-15 | 2022-03-22 | Chugai Pharmaceutical Co Ltd | Molécula de ligação a antígeno, composição farmacêutica, e método |
| EP4013785A4 (en) * | 2019-08-12 | 2023-12-20 | CSL Innovation Pty Ltd | COMPLEMENT C2-BINDING PROTEINS AND THEIR USE |
| EP4062933A4 (en) | 2019-11-20 | 2023-12-13 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing preparation |
| WO2021216458A1 (en) | 2020-04-20 | 2021-10-28 | Genzyme Corporation | Humanized anti-complement factor bb antibodies and uses thereof |
| EP4146276A4 (en) * | 2020-05-05 | 2024-08-14 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Compositions and methods for treating epilepsy |
| WO2021231211A1 (en) * | 2020-05-11 | 2021-11-18 | Genentech, Inc. | Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same |
| MX2023001492A (es) | 2020-08-06 | 2023-03-08 | Bioverativ Usa Inc | Citocinas inflamatorias y fatiga en sujetos con una enfermedad mediada por el complemento. |
| EP4277663A4 (en) * | 2021-01-14 | 2025-06-25 | The Board of Trustees of the Leland Stanford Junior University | ACTIVE DELIVERY OF RADIOTRACERS ACROSS THE BLOOD-BRAIN BARRIER |
| WO2022212645A1 (en) | 2021-03-31 | 2022-10-06 | Bioverativ Usa Inc. | Reducing surgery-associated hemolysis in cold agglutinin disease patients |
| CN117769434A (zh) * | 2021-05-20 | 2024-03-26 | 黛安瑟斯医疗运营公司 | 与C1s结合的抗体和其用途 |
| CN117642431B (zh) * | 2021-07-13 | 2025-07-15 | 迈威(美国)生物治疗有限公司 | 抗c1s抗体和其用途 |
| US12486322B2 (en) | 2021-12-13 | 2025-12-02 | Annexon, Inc. | Anti-complement factor C1q antibodies with single binding arms and uses thereof |
| CN114874329A (zh) * | 2022-05-19 | 2022-08-09 | 江苏大学 | 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用 |
| CN120344263A (zh) * | 2022-11-21 | 2025-07-18 | 黛安瑟斯医疗运营公司 | 结合c1s的抗体和其用途 |
| WO2025129535A1 (en) * | 2023-12-20 | 2025-06-26 | Dianthus Therapeutics Opco, Inc. | Pharmaceutical compositions comprising antibodies for treatment of c1s mediated disorders and methods of using the same |
| US20250206814A1 (en) * | 2023-12-20 | 2025-06-26 | Dianthus Therapeutics Opco, Inc. | Pharmaceutical compositions comprising antibodies for treatment of c1s mediated disorders and methods of using the same |
| CN118259018B (zh) * | 2024-03-21 | 2024-10-29 | 泰州市人民医院 | C1s抗体制备及其在ITP诊断中的应用 |
Family Cites Families (155)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS60192263A (ja) | 1984-03-13 | 1985-09-30 | Teijin Ltd | 免疫複合体測定用標準物質及びそれを用いた免疫複合体の測定法 |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| CA1276103C (en) | 1984-10-02 | 1990-11-13 | Fumiaki Taguchi | Substance-conjugated complement component c1q |
| JPS61271455A (ja) | 1985-05-28 | 1986-12-01 | Olympus Optical Co Ltd | 免疫学的分析方法 |
| EP0226660B1 (de) | 1985-12-24 | 1989-07-12 | O & K Orenstein & Koppel Aktiengesellschaft | Schaufelradschneidvorrichtung |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4866132A (en) | 1986-04-17 | 1989-09-12 | The Research Foundation Of State University Of New York | Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| US5256334A (en) | 1988-09-08 | 1993-10-26 | The Research Foundation Of The State University Of New York | Homogeneous radiopaque polymer-organobismuth composites |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| AU663725B2 (en) | 1991-08-20 | 1995-10-19 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| JPH08503855A (ja) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | 嚢胞性線維症に対する遺伝子治療 |
| US5346981A (en) | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| AU678064B2 (en) | 1993-09-01 | 1997-05-15 | Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis | Method to reduce myocardial injury during acute myocardial infarction |
| SK283703B6 (sk) | 1993-10-25 | 2003-12-02 | Canji, Inc. | Rekombinantný adenovírusový vektor a jeho použitie |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
| KR100551104B1 (ko) | 1994-12-09 | 2006-02-09 | 임페리얼 컬리지 이노베이션스 리미티드 | 유전자의 동정 |
| AU4188196A (en) | 1994-12-22 | 1996-07-10 | Nissan Chemical Industries Ltd. | Organobismuth derivatives and process for producing the same |
| US5958713A (en) | 1995-01-31 | 1999-09-28 | Novo Nordisk A/S | Method of detecting biologically active substances by using green fluorescent protein |
| US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| US5968738A (en) | 1995-12-06 | 1999-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Two-reporter FACS analysis of mammalian cells using green fluorescent proteins |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US6020192A (en) | 1996-01-18 | 2000-02-01 | University Of Florida | Humanized green fluorescent protein genes and methods |
| US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| JP4162267B2 (ja) | 1996-08-27 | 2008-10-08 | カイロン コーポレイション | Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法 |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| TW371617B (en) | 1996-10-09 | 1999-10-11 | Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau | Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV |
| US6969601B2 (en) | 1997-04-03 | 2005-11-29 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| AR014621A1 (es) | 1997-12-12 | 2001-03-28 | Macromed Inc | Un poli (etilenglicol) con forma de estrella, heterofuncional, biocompatible, metodo para su obtencion y metodo para conjugarlo con una proteina |
| CN101298481A (zh) | 1998-02-20 | 2008-11-05 | 吉宁特有限公司 | 补体活化的抑制剂 |
| US5985577A (en) | 1998-10-14 | 1999-11-16 | The Trustees Of Columbia University In The City Of New York | Protein conjugates containing multimers of green fluorescent protein |
| JP2003529536A (ja) | 1999-02-09 | 2003-10-07 | ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド | Ｃ１ｓ介在疾患および状態の処置法、およびそれのための化合物および組成物 |
| WO2000064327A2 (en) | 1999-04-26 | 2000-11-02 | Duke University | Inhibition of complement action |
| WO2001013945A1 (en) | 1999-08-23 | 2001-03-01 | Biocrystal Ltd. | Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis |
| WO2001053825A1 (en) | 2000-01-19 | 2001-07-26 | Biotransplant, Inc. | Swine defective for transmission of porcine endogenous retrovirus and uses thereof |
| DE122011000002I1 (de) | 2000-01-31 | 2011-05-05 | Pharming Intellectual Pty Bv | Humaner c1 inhibitor hergestellt in der milch transgener säugetiere |
| US6998468B2 (en) | 2000-03-23 | 2006-02-14 | Tanox, Inc. | Anti-C2/C2a inhibitors of complement activation |
| AU2001282857A1 (en) * | 2000-06-21 | 2002-01-02 | Zymogenetics Inc. | Peptide and polypeptide inhibitors of complement c1s |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| WO2003009803A2 (en) | 2001-07-26 | 2003-02-06 | Alexion Pharmaceuticals Inc. | Method of improving cognitive function |
| IL160701A0 (en) | 2001-09-21 | 2004-08-31 | Mitsubishi Pharma Corp | 3-substituted-4-pyrimidone derivatives |
| NZ533692A (en) | 2002-01-11 | 2006-09-29 | Gtc Biotherapeutics Inc | Improved methods for the fusion and activation of reconstructed embryos for use in nuclear transfer procedures in non-human mammals |
| US20080206242A1 (en) | 2002-03-01 | 2008-08-28 | Xencor, Inc. | Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies |
| SE0202880D0 (sv) | 2002-07-26 | 2002-09-30 | Wieslab Ab | Complement system deficiency assay |
| US7666627B2 (en) | 2002-08-08 | 2010-02-23 | Targetex Kft. | Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof |
| AU2003270330B2 (en) | 2002-09-06 | 2009-07-30 | Alexion Pharmaceuticals, Inc. | Method of treatment of asthma using antibodies to complement component C5 |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US7361339B2 (en) | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
| CN1787741B (zh) | 2003-05-15 | 2011-08-17 | 唐纳士公司 | 用于预防和治疗败血症的方法与组合物 |
| WO2005014849A2 (en) | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
| US7482376B2 (en) * | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
| WO2005025509A2 (en) | 2003-09-11 | 2005-03-24 | Board Of Regents, The University Of Texas System | Methods and materials for treating autoimmune diseases and conditions |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| WO2005035754A1 (ja) | 2003-10-14 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| CN1942483B (zh) | 2004-04-13 | 2012-09-26 | 弗·哈夫曼-拉罗切有限公司 | 抗p型选凝素抗体 |
| US8951522B2 (en) | 2011-04-08 | 2015-02-10 | University Of Leicester | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20060018896A1 (en) | 2004-06-10 | 2006-01-26 | University Of Leicester | Methods for treating conditions associated with lectin-dependent complement activation |
| PL2465534T3 (pl) | 2004-06-10 | 2017-08-31 | Omeros Corporation | Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2 |
| US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| KR101699142B1 (ko) | 2004-06-18 | 2017-01-23 | 암브룩스, 인코포레이티드 | 신규 항원-결합 폴리펩티드 및 이의 용도 |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| DK1817340T3 (da) | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| AU2005313971B2 (en) | 2004-12-08 | 2011-10-13 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
| US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| AU2006227778A1 (en) | 2005-03-16 | 2006-09-28 | Janssen Pharmaceutica N.V. | Novel thiophene sulfoximines for treating complement-mediated diseases and conditions |
| US8163881B2 (en) | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
| EP1893227A2 (en) | 2005-06-06 | 2008-03-05 | Girish J. Kotwal | Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury |
| US8124076B2 (en) * | 2005-08-18 | 2012-02-28 | Ramot At Tel Aviv University Ltd. | Single chain antibodies against β-amyloid peptide |
| US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| WO2007047995A2 (en) | 2005-10-21 | 2007-04-26 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
| US9480658B2 (en) | 2005-12-09 | 2016-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of synaptic maintenance |
| US8148330B2 (en) | 2005-12-09 | 2012-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of synaptic maintenance |
| SI2380587T1 (en) | 2005-12-21 | 2018-03-30 | Pharming Intellectual Property B.V. | Use of a C1 inhibitor to prevent ischemic reperfusion injury |
| FR2897868B1 (fr) | 2006-02-24 | 2012-08-31 | Lab Francais Du Fractionnement | Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii. |
| CA3009846C (en) | 2006-03-08 | 2021-08-31 | David Epstein | Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders |
| AR060040A1 (es) * | 2006-03-21 | 2008-05-21 | Genentech Inc | Antagonistas de vefg y de alfa5 beta 1 |
| US9388235B2 (en) | 2006-09-05 | 2016-07-12 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| NZ576195A (en) | 2006-10-10 | 2012-04-27 | Az Univ Amsterdam | Complement inhibition for improved nerve regeneration |
| US7858752B2 (en) | 2006-12-05 | 2010-12-28 | Abbott Laboratories | Recombinant antibodies against hepatitis C virus and methods of obtaining and using same |
| WO2008074227A1 (en) | 2006-12-19 | 2008-06-26 | Versitech Limited | Synthetic ion channels |
| WO2008097525A2 (en) | 2007-02-05 | 2008-08-14 | Potentia Pharmaceuticals, Inc. | Local complement inhibition for treatment of complement-mediated disorders |
| US8192742B2 (en) * | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| NZ583367A (en) | 2007-07-16 | 2012-10-26 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
| CA2693852C (en) | 2007-08-03 | 2016-11-29 | Genentech, Inc. | Humanized anti-fgf19 antagonists and methods using same |
| PL2808343T3 (pl) | 2007-12-26 | 2019-11-29 | Xencor Inc | Warianty Fc ze zmienionym wiązaniem do FcRn |
| WO2009121065A2 (en) | 2008-03-28 | 2009-10-01 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
| JP5739326B2 (ja) | 2008-04-25 | 2015-06-24 | ザイモジェネティクス， インコーポレイテッド | Ｂ細胞上でのｂｃｍａタンパク発現レベル及び診断法における使用 |
| WO2010033279A2 (en) | 2008-06-04 | 2010-03-25 | Macrogenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
| WO2009151634A1 (en) | 2008-06-12 | 2009-12-17 | The Board Of Trustees Of The Leland Stanford Junior University | Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| WO2010047830A2 (en) * | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | Agents for hcv treatment |
| HUE061548T2 (hu) | 2008-11-10 | 2023-07-28 | Alexion Pharma Inc | Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények |
| WO2010065425A1 (en) | 2008-12-01 | 2010-06-10 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for detection of complement fixing antibodies |
| WO2010063785A2 (en) | 2008-12-03 | 2010-06-10 | Genmab A/S | Antibody variants having modifications in the constant region |
| US8401799B2 (en) | 2008-12-05 | 2013-03-19 | Lpath, Inc. | Antibody design using anti-lipid antibody crystal structures |
| BRPI0923283A2 (pt) | 2008-12-05 | 2017-06-06 | Angiochem Inc | conjugados terapêuticos de peptídeo e usos dos mesmos |
| US20100291106A1 (en) | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| US20110002931A1 (en) * | 2009-06-23 | 2011-01-06 | Alexion Pharmaceuticals, Inc. | Bispecific antibodies that bind to complement proteins |
| TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| AU2010306581B2 (en) | 2009-10-16 | 2015-03-19 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation |
| JP5851391B2 (ja) | 2010-02-16 | 2016-02-03 | 国立大学法人京都工芸繊維大学 | 抗体固定化担体、抗体固定化担体の製造方法および当該抗体固定化担体の利用 |
| NZ602219A (en) | 2010-03-01 | 2014-10-31 | Alexion Pharma Inc | Methods and compositions for treating degos’ disease |
| EA028899B1 (ru) | 2010-04-30 | 2018-01-31 | Алексион Фармасьютикалз, Инк. | АНТИ-C5a-АНТИТЕЛА И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ |
| WO2011146514A2 (en) | 2010-05-17 | 2011-11-24 | The Board Of Regents Of The University Of Texas System | Rapid isolation of monoclonal antibodies from animals |
| CN103249432A (zh) | 2010-06-22 | 2013-08-14 | 科罗拉多大学董事会,法人团体 | 补体成分3的C3d片段的抗体 |
| US9421240B2 (en) | 2010-06-22 | 2016-08-23 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| TWI560199B (en) | 2010-08-31 | 2016-12-01 | Sanofi Sa | Peptide or peptide complex binding to α2 integrin and methods and uses involving the same |
| TW201241008A (en) | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| US8865164B2 (en) | 2010-11-02 | 2014-10-21 | Kypha, Inc. | Detecting complement activation |
| MX379481B (es) | 2010-12-06 | 2025-03-11 | Seagen Inc | Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer |
| JP6147670B2 (ja) | 2010-12-22 | 2017-06-14 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 改善された半減期を有する修飾された抗体 |
| EP3725811A3 (en) | 2011-05-04 | 2021-01-27 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement activation |
| US9289467B2 (en) | 2011-08-10 | 2016-03-22 | Case Western Reserve University | Compositions and methods for treating bone conditions |
| US9452203B2 (en) | 2011-12-22 | 2016-09-27 | Csl Behring Gmbh | Use of C1-inhibitor for the treatment of secondary edema of the central nervous system |
| JP6081699B2 (ja) | 2011-12-28 | 2017-02-15 | 雅史 溝上 | Ｉｌ−２８ｂの分析方法 |
| KR102041412B1 (ko) | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Ｆｃ 단편 유도체 |
| CN104870475B (zh) | 2012-10-25 | 2019-11-08 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| CA2889197A1 (en) * | 2012-11-02 | 2014-05-08 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| EP2975055A4 (en) | 2013-01-31 | 2016-11-02 | Univ Seoul Nat R & Db Found | C5 ANTIBODIES AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-MEDIATED ILLNESSES |
| US20140294812A1 (en) | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| US20160090425A1 (en) | 2013-05-15 | 2016-03-31 | Annexon, Inc. | Anti-complement factor c1s antibodies and uses thereof |
| US9944717B2 (en) | 2013-05-23 | 2018-04-17 | Broteio Pharma B.V. | Binding molecules that bind human complement factor C2 and uses thereof |
| BR112016000106B1 (pt) | 2013-07-09 | 2023-11-21 | Annexon, Inc. | Anticorpos anti-c1q e usos dos mesmos, célula de hibridoma, composição farmacêutica e métodos de detecção de sinapses em uma amostra biológica referências cruzadas a pedidos relacionados |
| WO2015084999A1 (en) | 2013-12-06 | 2015-06-11 | True North Therapeutics, Inc. | Complement component biomarker assays |
| BR112017007393A2 (pt) | 2014-10-18 | 2017-12-19 | Pfizer | composições de anticorpo anti-il-7r |
| PT3280440T (pt) | 2015-04-06 | 2023-02-14 | Bioverativ Usa Inc | Anticorpos anti-c1s humanizados e métodos de utilização destes |
| WO2016210172A1 (en) | 2015-06-26 | 2016-12-29 | True North Therapeutics, Inc. | Methods of treating autoimmune and alloimmune disorders |
| CN116554320A (zh) | 2016-10-12 | 2023-08-08 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| BR112019018950A2 (pt) | 2017-03-14 | 2020-04-22 | Bioverativ Usa Inc. | métodos para tratamento de doenças e distúrbios mediados por complemento |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| KR20200143459A (ko) | 2018-04-13 | 2020-12-23 | 추가이 세이야쿠 가부시키가이샤 | 항-보체 성분 항체 및 사용 방법 |
| JP7467438B2 (ja) | 2018-10-18 | 2024-04-15 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｒｓｖ抗体の製剤及びその使用方法 |
| MX2023001492A (es) | 2020-08-06 | 2023-03-08 | Bioverativ Usa Inc | Citocinas inflamatorias y fatiga en sujetos con una enfermedad mediada por el complemento. |
| WO2022212645A1 (en) | 2021-03-31 | 2022-10-06 | Bioverativ Usa Inc. | Reducing surgery-associated hemolysis in cold agglutinin disease patients |
| WO2023250507A1 (en) | 2022-06-24 | 2023-12-28 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
-
2013
- 2013-11-01 CA CA2889197A patent/CA2889197A1/en active Pending
- 2013-11-01 EP EP13851256.1A patent/EP2914291B1/en active Active
- 2013-11-01 ES ES13851256T patent/ES2912396T3/es active Active
- 2013-11-01 EP EP21157955.2A patent/EP3906944A1/en active Pending
- 2013-11-01 HR HRP20220637TT patent/HRP20220637T1/hr unknown
- 2013-11-01 DK DK13851256.1T patent/DK2914291T3/da active
- 2013-11-01 PT PT138512561T patent/PT2914291T/pt unknown
- 2013-11-01 JP JP2015540826A patent/JP6543572B2/ja active Active
- 2013-11-01 CN CN201380068801.5A patent/CN104884088B/zh active Active
- 2013-11-01 AU AU2013337638A patent/AU2013337638B2/en active Active
- 2013-11-01 GB GB1403961.4A patent/GB2509260B/en active Active
- 2013-11-01 PL PL13851256.1T patent/PL2914291T3/pl unknown
- 2013-11-01 US US14/070,186 patent/US8945562B2/en active Active
- 2013-11-01 RS RS20220439A patent/RS63212B1/sr unknown
- 2013-11-01 LT LTEPPCT/US2013/068095T patent/LT2914291T/lt unknown
- 2013-11-01 CN CN202211418763.9A patent/CN116063483A/zh active Pending
- 2013-11-01 CN CN201810462335.3A patent/CN108610418B/zh active Active
- 2013-11-01 WO PCT/US2013/068095 patent/WO2014071206A1/en not_active Ceased
-
2014
- 2014-01-10 US US14/152,684 patent/US9074003B2/en active Active
- 2014-01-10 US US14/152,565 patent/US8877197B2/en active Active
- 2014-10-24 US US14/523,093 patent/US9074004B2/en active Active
-
2015
- 2015-05-11 US US14/709,277 patent/US9206259B2/en active Active
- 2015-11-04 US US14/932,174 patent/US9562092B2/en active Active
-
2016
- 2016-12-20 US US15/385,735 patent/US10450382B2/en active Active
-
2019
- 2019-01-23 AU AU2019200448A patent/AU2019200448B2/en active Active
- 2019-06-17 JP JP2019111910A patent/JP6860618B2/ja active Active
- 2019-09-05 US US16/561,202 patent/US20200079875A1/en not_active Abandoned
-
2021
- 2021-03-22 AU AU2021201759A patent/AU2021201759A1/en not_active Abandoned
- 2021-03-26 JP JP2021052645A patent/JP7210629B2/ja active Active
- 2021-12-10 US US17/548,135 patent/US12240917B2/en active Active
-
2023
- 2023-01-11 JP JP2023002363A patent/JP2023052318A/ja not_active Withdrawn
- 2023-03-14 LT LTPA2023510C patent/LTC2914291I2/lt unknown
- 2023-03-22 LU LU00303C patent/LUC00303I2/en unknown
- 2023-04-17 FI FIC20230015C patent/FIC20230015I1/fi unknown
- 2023-04-26 NO NO2023018C patent/NO2023018I1/no unknown
- 2023-04-27 HU HUS2300017C patent/HUS2300017I1/hu unknown
- 2023-05-11 NL NL301232C patent/NL301232I2/nl unknown
- 2023-05-12 FR FR23C1019C patent/FR23C1019I2/fr active Active
-
2024
- 2024-10-23 AU AU2024227570A patent/AU2024227570A1/en active Pending
-
2025
- 2025-03-03 US US19/068,758 patent/US20250188192A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016505240A5 (enExample) | ||
| JP6466401B2 (ja) | ヒト化抗ｃｄ１９キメラ抗原受容体を使用するがんの処置 | |
| US10858420B2 (en) | Methods of treating hemolytic disorders comprising administering an anti-C3b antibody | |
| US11780921B2 (en) | Antibodies to programmed cell death protein 1 | |
| JP2025108730A (ja) | 造血幹細胞移植に関連する移植片対宿主病および／またはびまん性肺胞出血および／または静脈閉塞症を治療および／または予防するための方法 | |
| UA126657C2 (uk) | ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font> | |
| BR112018009972B1 (pt) | Ligante de ctla4, ligante, recipiente ou dispositivo de injeção, polinucleotídeo, vetor, célula hospedeira, métodos para fabricar o ligante de ctla4 e para prevenir que ctla4 se ligue à cd80 ou cd86 e usos do referido ligante de ctla4 | |
| JP2018531986A (ja) | Ｐｄ−１抗体 | |
| US20210403548A1 (en) | Treating vascular disease and complications thereof | |
| CN110407938B (zh) | 抗tim-3单克隆抗体、表达载体及其应用 | |
| UA125136C2 (uk) | Антитіла, які зв'язуються з сортиліном і пригнічують зв'язування програнуліну | |
| JPWO2013183786A1 (ja) | トランスポーターに対する抗体およびその用途 | |
| KR20230088370A (ko) | Cd47-cd38 이중특이성 항체 | |
| TWI605059B (zh) | Inflammatory disease treatment agent | |
| JP2024544057A (ja) | 血栓塞栓性疾患を予防及び／又は治療する方法 | |
| RU2736650C2 (ru) | Активатор регуляторных t-клеток и его применение | |
| CN110945128A (zh) | 用于治疗肺纤维化的组合物和方法 | |
| KR20250007539A (ko) | Cd3/bcma/cd38 삼중특이적 항체 | |
| JP7533330B2 (ja) | Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療 | |
| WO2024256527A1 (en) | Use of a cxcl 10 inhibitor for the treatment of transplant vasculopathy | |
| HK40053657A (en) | Treating vascular disease and complications thereof | |
| JPWO2013125687A1 (ja) | 炎症疾患治療剤 |